Andrew Dunford

Andrew Dunford

Auto-generated profile, based on publicly available information

Andrew Dunford

Cancer Program Broad Institute of MIT and Harvard 02142 Cambridge MA USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 December 2019 in Blood Advances
Verified
Journal Article
Open access
PDF file
KWKirsty Wienand
Kirsty Wienand
BCBjörn Chapuy
Björn Chapuy
CSChip Stewart
Chip Stewart
ADAndrew J. Dunford
Andrew J. Dunford
DWDavid Wu
David Wu
MSMargaret A. Shipp
Margaret A. Shipp
Key Points: Analyses of recurrent mutations, copy number alterations, and structural variants reveal complementary immune evasion mechanisms in cHL. The mutational burden in EBV– cHLs is among the highest reported, potentially contributing to the efficacy of PD-1 blockade.

26 December 2019 in Blood
Verified
Journal Article
Open access
PDF file
BCBjörn Chapuy
Björn Chapuy
CSChip Stewart
Chip Stewart
ADAndrew J. Dunford
Andrew J. Dunford
JKJaegil Kim
Jaegil Kim
KWKirsty Wienand
Kirsty Wienand
MSMargaret A. Shipp
Margaret A. Shipp
A deep dive into genomic aberrations in 37 new diagnoses of primary mediastinal B-cell lymphoma (PMBL) reveals a surprisingly high number of driver mutations as well as genetic and epigenetic explanations for immune evasion by the tumor.

1 May 2025 in Blood
Verified
Journal Article
Closed access
BCBjörn Chapuy
Björn Chapuy
TWTimothy Wood
Timothy Wood
CSChip Stewart
Chip Stewart
ADAndrew Dunford
Andrew Dunford
KWKirsty Wienand
Kirsty Wienand
GGGad Getz
Gad Getz
Diffuse large B-cell lymphoma (DLBCL) is a clinically and molecularly heterogeneous disease. The increasing recognition and targeting of genetically defined DLBCLs highlight the need for robust classification algorithms. We previously characterized recurrent genetic alterations in DLBCL and identified 5 discrete subtypes, clusters 1 to 5 (C1-C5), with unique mechanisms of transformation, immune evasion, candidate treatment targets, and different outcomes after standard first-line therapy. Herein, we validate the C1 to C5 DLBCL taxonomy in an independent data set and use the expanded series of 699 primary DLBCLs to develop a probabilistic molecular classifier and confirm its performance in an independent test set. Using our previously assigned cluster labels as a reference, we systematically compared multiple machine learning models and strategies for input feature dimensionality reduction with a newly developed performance metric that captured the relationship between accuracy and confidence of class assignments. The winning neural network model, DLBclass, assigned all cases in the training/validation and independent test sets with 91% and 89% accuracies, respectively. In the 75% of cases with confidence >0.7, DLBclass assignments were accurate in 97% of the training/validation set and 98% of the test set. DLBclass enables robust prospective classification of single cases for inclusion in genetically guided clinical trials or practice and represents a framework for the development of genomics-based classification methods in other cancers.

7 December 2022 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
ADAnkit K. Dutta
Ankit K. Dutta
JAJean-Baptiste Alberge
Jean-Baptiste Alberge
ELElizabeth D. Lightbody
Elizabeth D. Lightbody
CBCody J. Boehner
Cody J. Boehner
ADAndrew Dunford
Andrew Dunford
IGIrene M. Ghobrial
Irene M. Ghobrial
Multiple myeloma (MM) develops from well-defined precursor stages; however, invasive bone marrow (BM) biopsy limits screening and monitoring strategies for patients. We enumerated circulating tumor cells (CTC) from 261 patients (84 monoclonal gammopathy of undetermined significance, 155 smoldering multiple myeloma, and 22 MM), with neoplastic cells detected in 84%. We developed a novel approach, MinimuMM-seq, which enables the detection of translocations and copy-number abnormalities through whole-genome sequencing of highly pure CTCs. Application to CTCs in a cohort of 51 patients, 24 with paired BM, was able to detect 100% of clinically reported BM biopsy events and could replace molecular cytogenetics for diagnostic yield and risk classification. Longitudinal sampling of CTCs in 8 patients revealed major clones could be tracked in the blood, with clonal evolution and shifting dynamics of subclones over time. Our findings provide proof of concept that CTC detection and genomic profiling could be used clinically for monitoring and managing disease in MM. Significance: In this study, we established an approach enabling the enumeration and sequencing of CTCs to replace standard molecular cytogenetics. CTCs harbored the same pathognomonic MM abnormalities as BM plasma cells. Longitudinal sampling of serial CTCs was able to track clonal dynamics over time and detect the emergence of high-risk genetic subclones. This article is highlighted in the In This Issue feature, p. 247

18 December 2023 in Cancer Research Communications
Verified
Journal Article
Open access
PDF file
Tarek MouhieddineTarek Mouhieddine
Tarek Mouhieddine
CNChidimma Nzerem
Chidimma Nzerem
RRRobert Redd
Robert Redd
ADAndrew Dunford
Andrew Dunford
MLMatthew Leventhal
Matthew Leventhal
GGGad Getz
Gad Getz
Clonal hematopoiesis (CH) at time of autologous stem cell transplant (ASCT) has been shown to be associated with decreased overall survival (OS) and progression-free survival (PFS) in patients with multiple myeloma not receiving immunomodulatory drugs (IMiD). However, the significance of CH in newly diagnosed patients, including transplant ineligible patients, and its effect on clonal evolution during multiple myeloma therapy in the era of novel agents, has not been well studied. Using our new algorithm to differentiate tumor and germline mutations from CH, we detected CH in approximately 10% of 986 patients with multiple myeloma from the Clinical Outcomes in MM to Personal Assessment of Genetic Profile (CoMMpass) cohort (40/529 transplanted and 59/457 non-transplanted patients). CH was associated with increased age, risk of recurrent bacterial infections and cardiovascular disease. CH at time of multiple myeloma diagnosis was not associated with inferior OS or PFS regardless of undergoing ASCT, and all patients benefited from IMiD-based therapies, irrespective of the presence of CH. Serial sampling of 52 patients revealed the emergence of CH over a median of 3 years of treatment, increasing its prevalence to 25%, mostly with DNMT3A mutations. Significance: Using our algorithm to differentiate tumor and germline mutations from CH mutations, we detected CH in approximately 10% of patients with newly diagnosed myeloma, including both transplant eligible and ineligible patients. Receiving IMiDs improved outcomes irrespective of CH status, but the prevalence of CH significantly rose throughout myeloma-directed therapy.

3 April 2023
Verified
Other
Open access
EPEirini Pectasides
Eirini Pectasides
MSMatthew D. Stachler
Matthew D. Stachler
SDSarah Derks
Sarah Derks
YLYang Liu
Yang Liu
SMSteven Maron
Steven Maron
Daniel VT CatenacciDaniel VT Catenacci
Daniel VT Catenacci